Oncology Pipeline

Investigational drugs mentioned are for use in clinical studies only, and may be studied alone or in combination with drugs for indications that have not been approved by the FDA. Approved drugs mentioned are also being studied for uses for which they are not approved. Safety and efficacy have not been established for any of these drugs for the uses being studied. AbbVie in no way intends to recommend or imply that these drugs should be used for unapproved uses.




ABBV-1480 (RC148) developed in partnership with RemeGen; ABBV-2001 developed in partnership with Ichnos Glenmark Innovation (IGI); Alveltamig developed by Suzhou Zelgen Biopharmaceuticals. AbbVie holds an exclusive option to develop and commercialize Alveltamig; KST-6051 developed by Kestrel Therapeutics. AbbVie holds an exclusive option to acquire Kestrel; Epcoritamab developed in partnership with Genmab; SIM0500 developed by Simcere Zaiming. AbbVie holds an exclusive option to develop and commercialize SIM0500; UB-VV111 developed by Umoja Biopharma. AbbVie holds an exclusive option to develop and commercialize UB-VV111; Venetoclax jointly developed with Roche. Ibrutinib jointly developed with Janssen Biotech.
ADC=Antibody-Drug Conjugate.
mAb=Monoclonal Antibody.
Antigen Receptor T-Cell.
BsAb=Bispecific Antibody.
TsAb=Trispecific Antibody.